PDGFRα-positive mesenchymal stem/stromal cells contribute to autonomous vascular formation through in-body tissue architecture
Morikawa S., Yoda M., Ouchi T., Yasui T., Fukuda K., Sugimoto M.
Animal Study, published in PLoS One (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- PLoS One (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41990006
- PMCID
- PMC13086343
- DOI
- 10.1371/journal.pone.0347197
Abstract (original English)
Driven by endogenous platelet-derived growth factor receptor α (PDGFRα)-positive cells, in-body tissue architecture (iBTA) enables the autonomous formation of vascularized tissues within subcutaneously implanted molds, overcoming the limitations of traditional cell therapies. The cellular mechanisms were investigated in PDGFRα reporter mice. Recruited PDGFRα-lineage cells were closely associated with Pecam-1-positive vessels and often adopted perivascular positions. Flow cytometry revealed that these cells expressed the mesenchymal stem/stromal cell (MSC) markers (CD73, CD90, and CD105). Additionally, the cultured isolates maintained MSC morphology and demonstrated osteogenic, chondrogenic, and adipogenic differentiation potential in vitro. The approach was successfully scaled to a porcine model, which exhibited organized tissue maturation, including vascular structures and collagen deposition, within 2 weeks. iBTA eliminates the need for cell isolation and immunosuppression by leveraging resident PDGFRα-positive MSCs for in situ tissue generation, providing a direct pathway for autologous vascular tissue engineering applications.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.